The development of anti-HER2 therapy that started with the monoclonal antibody trastuzumab (Herceptin), which binds the extracellular domain of HER2, has revolutionised the management of HER2-positive breast cancer and become a paradigm for personalised medicine. The gene discussed is ERBB2; the disease is breast carcinoma.